PRELUDE THERAPEUTICS INC Payments to Acquire Marketable Securities
PRELUDE THERAPEUTICS INC (PRLD) reported Payments to Acquire Marketable Securities of $89.97 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC payments to acquire marketable securities for the quarter ending 2026-06-30 was $89.97M, a 264.77% increase year-over-year.
- PRELUDE THERAPEUTICS INC payments to acquire marketable securities for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- PRELUDE THERAPEUTICS INC payments to acquire marketable securities for the quarter ending 2025-12-31 was $66.74M, a 810.74% increase year-over-year.
- PRELUDE THERAPEUTICS INC payments to acquire marketable securities for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- PRELUDE THERAPEUTICS INC payments to acquire marketable securities for fiscal 2025 was $100.87M, a 91.42% increase from fiscal 2024.
- PRELUDE THERAPEUTICS INC payments to acquire marketable securities for fiscal 2024 was $52.69M, a 76.22% decline from fiscal 2023.
- PRELUDE THERAPEUTICS INC payments to acquire marketable securities for fiscal 2023 was $221.63M, a 85.90% increase from fiscal 2022.
- PRELUDE THERAPEUTICS INC payments to acquire marketable securities for fiscal 2022 was $119.22M, a 54.40% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $89.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $89.97M 10-Q · filed 2026-08-11 | $156.71M derived: sum of 3 quarters · filed 2026-08-11 | $156.71M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $66.74M derived: sum of 2 quarters · filed 2026-05-12 | $66.74M derived: sum of 3 quarters · filed 2026-05-12 | $91.40M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $66.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $66.74M derived: sum of 2 quarters · filed 2026-03-10 | $91.40M derived: sum of 3 quarters · filed 2026-08-11 | $100.87M 10-K · filed 2026-03-10 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $24.66M derived: sum of 2 quarters · filed 2026-08-11 | $34.13M 10-Q · filed 2025-11-12 | $41.45M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $24.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $34.13M 10-Q · filed 2026-08-11 | $41.45M derived: sum of 3 quarters · filed 2026-08-11 | $73.45M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $9.46M 10-Q · filed 2026-05-12 | $16.79M derived: sum of 2 quarters · filed 2026-05-12 | $48.78M derived: sum of 3 quarters · filed 2026-05-12 | $56.67M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $7.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $39.32M derived: sum of 2 quarters · filed 2026-03-10 | $47.20M derived: sum of 3 quarters · filed 2026-03-10 | $52.69M 10-K · filed 2026-03-10 |
| 2024-09-30 | $31.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $39.88M derived: sum of 2 quarters · filed 2025-11-12 | $45.37M 10-Q · filed 2025-11-12 | $104.75M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $7.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $13.37M 10-Q · filed 2025-08-14 | $72.76M derived: sum of 3 quarters · filed 2025-08-14 | $106.87M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $5.49M 10-Q · filed 2025-05-06 | $64.88M derived: sum of 2 quarters · filed 2025-05-06 | $98.99M derived: sum of 3 quarters · filed 2025-05-06 | $219.93M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $59.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $93.50M derived: sum of 2 quarters · filed 2025-03-10 | $214.44M derived: sum of 3 quarters · filed 2025-03-10 | $221.63M 10-K · filed 2025-03-10 |
| 2023-09-30 | $34.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $155.06M derived: sum of 2 quarters · filed 2024-11-06 | $162.25M 10-Q · filed 2024-11-06 | $195.50M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $120.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $128.13M 10-Q · filed 2024-08-12 | $161.38M derived: sum of 3 quarters · filed 2024-08-12 | $220.22M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $7.19M 10-Q · filed 2024-05-07 | $40.44M derived: sum of 2 quarters · filed 2024-05-07 | $99.27M derived: sum of 3 quarters · filed 2024-05-07 | |
| 2022-12-31 | $33.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $92.08M derived: sum of 2 quarters · filed 2024-02-15 | $119.22M 10-K · filed 2024-02-15 | |
| 2022-09-30 | $58.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $85.97M 10-Q · filed 2023-11-01 | ||
| 2022-06-30 | $27.14M 10-Q · filed 2023-08-03 | |||
| 2021-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $261.48M 10-K · filed 2023-03-15 | ||
| 2021-09-30 | $259.97M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |